COMMUNIQUÉS West-GlobeNewswire

Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
03/06/2025
Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart disease Southlake, TX, June 03, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: [...]
H1 Acquires Veda to Solve Healthcare’s Provider Data Challenge and Power Better Care
03/06/2025
Acquisition equips health plans with next-generation provider data management, enabling improved access to care and better health outcomes NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- H1 , on a mission to connect the [...]
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
03/06/2025
Company enters option agreement with JiKang Therapeutics to in-license novel APJ agonist antibody New composition of matter IP filed for chemically distinct, orally active, and highly potent small molecule APJ agonists [...]
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
03/06/2025
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of [...]
Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
03/06/2025
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic [...]
Visory Health Survey Reveals Critical Gap in Prescription Savings for Uninsured Spanish Speakers
03/06/2025
Nearly half of uninsured Spanish speakers are unfamiliar with prescription discount cards – a gap that’s putting affordable medications out of reach for millions ESTERO, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Visory [...]
CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform
03/06/2025
Dr. George Katibah and Dr. Adam Grant describe the features and progress of the Company’s revolutionary technology Lehi, June 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah – June 3rd, 2025 – CancerVax, Inc., the developer of [...]
Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases
03/06/2025
Financing co-led by new investor BRM Group and existing investor Pontifax Lead program KM023 is a first-in-class oral TRPV3 inhibitor entering clinical development for the treatment of three rare genetic skin diseases; [...]
Oculis to Participate in Upcoming June Investor Conferences
03/06/2025
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Oculis to Participate in Upcoming June Investor Conferences
03/06/2025
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]
Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
03/06/2025
Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing allo-HCT Saint-Louis, [...]
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
03/06/2025
June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl [...]
Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de la drépanocytose
03/06/2025
Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de la drépanocytose Quatrième désignation de médicament orphelin pour le rilzabrutinib dans les maladies rares En cours d’ [...]
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
03/06/2025
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseases Under regulatory review in the US, the EU, and China in immune [...]
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
03/06/2025
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First Phase III study in ES-SCLC first- [...]
Addex Convenes Annual General Meeting 2025
03/06/2025
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for [...]
Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat et un prix cible de 4,00 €
03/06/2025
Communiqué de presse Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat et un prix cible de 4,00 € Dijon, France le 3 juin 2025 (07h30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), [...]
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00
03/06/2025
Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the [...]
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
03/06/2025
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1 -m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of [...]

Pages